Document is current
Any future updates will be listed below
-
Authors
Dubler, Simon
Etringer, Michael
Lichtenstern, Christoph
Brenner, Thorsten
Zimmermann, Stefan
Schnitzler, Paul
Budeus, Bettina
Rengier, Fabian
Kalinowska, Paulina
Hoo, Yuan Lih
Weigand, Markus A.
-
Funding
Funding for this research was provided by:
Medizinische Fakultät Heidelberg der Universität Heidelberg
- License Information
-
More Information
Article History
Received: 25 August 2024
Accepted: 6 January 2025
First Online: 15 January 2025
Declarations
:
: Additional information with conflict-of-interest statement: Paul Schnitzler, Bettina Budeus, Yuan Lih Hoo, Fabian Rengier, Michael Etringer, Christoph Lichtenstern, Paulina Kalinowska and Stefan Zimmermann declare no conflict of interest. Simon Dubler received research funding from Stiftung Universitätsmedizin Essen (Essen, Germany). Simon Dubler received honoraria for lectures from Akademie für Infektionsmedizin e.V. Thorsten Brenner received grants from Deutsche Forschungsgemeinschaft (DFG), Dietmar Hopp Stiftung, Stiftung Universitätsmedizin Essen and Innovationsfonds des Gemeinsamen Bundesausschusses (G-BA). Thorsten Brenner received honoraria for lectures from CSL Behring GmbH, Schöchl medical education GmbH, Biotest AG, Baxter Deutschland GmbH, Boehringer Ingelheim Pharma GmbH, Astellas Pharma GmbH, B. Braun Melsungen AG, MSD Sharp & Dohme GmbH, Daiichi Sankyo Deutschland GmbH, Akademie für Infektionsmedizin e.V., Lücke Kongresse GmbH, Pfizer Deutschland GmbH, MVZ Labor Dr. Limbach & Kollegen GbR. TB pending patents with BRAHMS GmbH. Thorsten Brenner participation on advisory board with Baxter Deutschland GmbH and Bayer AG. Markus A. Weigand received grants from DFG-Graduate school and DZIF-TIARA Cohort. Markus A. Weigand received consulting fees from MSD, Mundipharma, Gilead, Pfizer, Shionogi, Eumedica, Coulter, Biotest, Sedana, SOBI and Böhringer. Markus A. Weigand received honoraria for lectures from MSD, Pfizer and Gilead. MAW pending patents on EPA / 25.10.17 / EPA 17198330, Delta like ligand for diagnosing severe infections. Markus A. Weigand leadership role in DSG and PEG.
